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Introduction and Aims. Monocyte chemoattractant protein- (MCP-) 1, macrophage colony-stimulating factor (MCSF), and
neopterin are connected with monocyte migration and transition into macrophages, leading to fibrosis and tubular damage in
the course of CKD. The aim of the study was to analyze the applicability of urinary fractional excretion (FE) of MCP1, MCSF,
and neopterin, as markers of inflammation and tubular damage, in children with CKD. Methods. The study group consisted of
61 children with CKD stages 1–5 and 23 age-matched controls. The serum and urine concentrations of MCP1, MCSF, and
neopterin were assessed by ELISA and then the fractional excretion (FE) was calculated. Results. FE MCSF and neopterin values
exceeded 1% already in controls. FE MCSF rose significantly since CKD stages 1-2, FE neopterin since CKD stages 3–5. FE
MCP1 was below 1% in healthy controls and in CKD stages 1-2, then increased significantly in CKD stages 3–5. Conclusions.
The FE MCP-1 values show that inflammation precedes the tubular dysfunction. FE MCSF and FE neopterin may be considered
new markers of the renal parenchyma progressive damage. Fractional excretion may become a useful tool in the assessment of
inflammation and tubular damage in children with CKD.
1. Introduction
Chronic kidney disease (CKD) is characterized by enhanced
migration of immunocompetent cells to the sites of
inflammation and subsequent renal fibrosis [1]. The latter
is an essential element of progressive and irreversible
tubular damage [2]. Various chemotactic agents influence
the abovementioned CKD-related complications.
Monocyte chemoattractant protein- (MCP-) 1 and
macrophage colony-stimulating factor (MCSF) control early
stages of cell migratory activity, such as movement of mono-
cytes to the sites of inflammation and their transition into
macrophages [3]. Thus, the activity of MCP-1 and MCSF
may be treated as a substitute of the inflammation process
intensity and monocyte and macrophage activity, as well as
the cell damage in the course of chemotactic migration and
transition. Animal studies have shown profibrotic activity
of MCP-1 and its localization in tubular cells [4, 5]. The
MCP-1 gene (MCP-1-2518 A/G) polymorphism has been
analyzed in adults on hemodialysis and in children with focal
segmental glomerulosclerosis [6, 7]. MCSF was assessed in
adults on hemodialysis [8]. However, MCP-1 or MCSF has
never been put into the focus of chronic kidney disease pro-
gression in children.
Neopterin was the only exception in this group, since
its production is not a cause, but a consequence of
enhanced cell migration and ongoing inflammation. In
detail, both monocytes and macrophages excrete neopterin
upon stimulation. Therefore, this molecule may be a marker
of cellular immune response. The increased serum and urine
concentrations of neopterin were observed in adults with
nephrotic syndrome, with advanced stages of CKD, and on
hemodialysis [9, 10]. The elevated excretion of neopterin
with urine was also noticed in adults with mesangial prolifer-
ative glomerulonephritis [11]. Neopterin was also useful as a
risk marker of renal allograft rejection [12].
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However, the abovementioned parameters have never
been analyzed as markers of inflammation or macrophage
activity in children with CKD.
In clinical practice, the analysis of fractional excretion
(FE) as a substitute of tubular dysfunction in the CKD
patients was restricted to phosphate metabolism so far
[13]. Scientific approach to FE concerned heat shock pro-
tein (Hsp27) in adults [14] and markers of apoptosis in
children from our previous study [15]. That investigation
confirmed the usefulness of FE in depicting tubular damage
and epithelial-mesenchymal transition in the patients with
CKD. However, neither MCP-1, MCSF, nor neopterin has
been tested, in the light of fractional excretion, as poten-
tial markers of tubular damage in the course of chronic
kidney disease.
Therefore, the aim of this study was to analyze the factors
engaged in monocyte activation, migration, and their transi-
tion into macrophages, by assessing the concentrations of
MCP-1, MCSF, and neopterin, in the serum and urine of
children with CKD and of controls. We also evaluated the
usefulness of fractional excretion (FE) of MCP-1, MCSF,
and neopterin as pluripotent markers of inflammation,
monocyte-macrophage interplay, and tubular damage in
the course of CKD.
2. Methods
2.1. Patient Characteristics. Eighty-four patients enrolled in
this study were divided into 3 groups. The first group
(CKD I) contained 20 children with CKD stages 1-2, and
the second group (CKD II) consisted of 41 patients with
CKD stages 3–5. Twenty-three children with primary noctur-
nal enuresis and normal kidney function served as controls.
Basic clinical data are shown in Table 1.
The diseases leading to CKDwere reflux nephropathy (19
cases), obstructive uropathy (14 patients), hypo-/dysplastic
kidneys (12), chronic glomerulonephritis (10), polycystic
kidney disease (4), and hemolytic uremic syndrome (2).
None of the patients has shown clinical evidence of infec-
tion; had diabetes, malignancies, or vasculitides; has smoked;
and took antibiotics and statins. The patients were also free of
such comorbidities like cardiovascular disease, peripheral
vascular disease, or obesity. In the CKD group, 35 children
were normotensive according to the criteria of the European
Society of Hypertension in children and adolescents [16]. In
16 patients, blood pressure was well controlled with the
use of ACE inhibitors (8 children), calcium channel
blockers (6 patients), and β-blockers (2 children), and 10
patients needed combined therapy. In all patients at
CKD stages 3–5, phosphate binders and vitamin D metab-
olites were supplemented.
Informed consent was obtained from the subjects and
their parents, if necessary. The research project has been
approved by the university ethics committee, in accordance
with the Helsinki declaration.
Blood samples were drawn from the peripheral veins
after an overnight fast. Samples were clotted for 30 minutes
and centrifuged for 10 minutes, and then serum was stored
at −20°C until assayed. Urine was collected aseptically from
the first morning sample, centrifuged for 10 minutes, and
then stored at −20°C until assayed.
2.2. Assay Characteristics. The serum and urine concentra-
tions of MCP-1, MCSF, and neopterin were evaluated by
commercially available ELISA kits (MCP-1—R&D Sys-
tems, reagent kit DCP00; MCSF—R&D Systems, reagent
kit DMC00B; neopterin—IBL International, reagent kit
RE59321). Standard, serum, and urine samples were trans-
ferred to 96-well microplates precoated with recombinant
antibodies to human MCP-1, MCSF, and neopterin. Mea-
surements were performed according to the manufacturer’s
instructions, and results were calculated by reference-to-
standard curves.
The serum and urine creatinine were assessed with the
Creatinine OSR61204 reagent on the Beckman Coulter
AU2700 analyzer.
The fractional parameter excretion was calculated
according to the formula ([urine parameter concentration]×
[serum creatinine concentration]) / ([serum parameter con-
centration]× [urine creatinine concentration])× 100%.
2.3. Statistical Analysis. The results are expressed as median
values and interquartile ranges. Since the null hypothesis
of normality of distribution was rejected by the Shapiro-
Wilk test, comparisons were evaluated by using nonpara-
metric tests (Kruskal-Wallis, Mann–Whitney U). Relations
between parameters were defined by Spearman’s correla-
tion coefficient R. Statistical analysis was performed using
the package Statistica ver. 12.0 (StatSoft). A p value < 0.05
was considered significant.
3. Results
3.1. Serum and Urine Concentrations of MCP-1, MCSF, and
Neopterin. The serum and urine concentrations of all exam-
ined parameters were significantly elevated, irrespective of
the CKD stage, versus controls (Tables 2 and 3). Serum
MCSF levels rose gradually with the CKD progression,
Table 1: Basic characteristics of the patients.
Parameters
Median (lower-upper quartile)
Control group (n = 23) CKD I (n = 20) CKD II (n = 41)
Age (years) 10.5 (5.0–16.5) 9.5 (4.0–12.5) 11.0 (4.5–16.5)
Gender
13 girls 5 girls 17 girls
10 boys 15 boys 24 boys
eGFR (ml/min/1.73m2) 97.1 (92.3–115.0) 79.5 (65.7–97.4) 26.2 (17.3–41.5)
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whereas serum MCP-1 and neopterin concentrations in
advanced stages of CKD were significantly lower than in
mild CKD, although still above the values seen in the
control group (Table 2).
Urine MCP-1 levels were significantly increased in CKD
stages 1-2 versus controls, but then remained stable despite
progression of CKD to stages 3–5 (Table 3). Urine MCSF
concentrations decreased in advanced versus mild CKD.
Urine neopterin levels were the only ones increasing
gradually with the CKD progression (Table 3).
Interestingly, the values of MCSF and neopterin in
urine were always higher than the relevant ones in serum,
irrespective of the analyzed group.
3.2. Fractional Excretion of MCP-1, MCSF, and Neopterin.
The fractional excretion (FE) of MCP-1 did not exceed 1%
in healthy controls, whereas it reached up to 5% in the case
of MCSF and neopterin (Table 4). Only MCP-1 and MCSF
FE values were significantly elevated in children with CKD
stages 1-2 versus controls, whereas all FE values were higher
in patients with CKD stages 3–5 versus those with CKD
stages 1-2 (Table 4). However, they remained below 1% for
MCP-1 in children with CKD stages 1-2. The fractional
excretion of MCSF and neopterin was far beyond 1% in all
CKD patients.
3.3. Correlations. The MCP-1, MCSF, and neopterin serum
levels correlated significantly with each other. In detail,
MCP-1 correlated positively with neopterin (R = 0 77;
p < 0 00001) and negatively with MCSF (R = −0 55;
p < 0 000001). Neopterin correlated negatively with MCSF
(R = −0 66; p < 0 000001). There was no correlation between
serum and urine values, although in the case of MCP-1, the
statistical significance was borderline (p = 0 057). The urine
concentrations of analyzed parameters did not correlate with
each other. None of the parameters correlated with eGFR.
4. Discussion
Our investigation has revealed elevated concentrations of
MCP-1, MCSF, and neopterin in the serum and urine of
children with chronic kidney disease in comparison to those
in the control group. However, the dynamics of these
changes differed between the analyzed molecules.
The MCP-1 concentrations in serum and urine have
risen significantly already in CKD stages 1-2. There are no
relevant data on MCP-1 levels in patients with CKD treated
conservatively; thus, the interpretation of these results
seemed challenging. Since none of the parameters has
correlated with eGFR, the source of serum elevation was
rather overproduction than accumulation, whereas increased
excretion with urine showed indirectly the monocyte activa-
tion in renal interstitium. This might mean that MCP-1 is a
useful marker of inflammation, and monocyte activity in
specific, both in serum and in urine. Moreover, since kidney
MCP-1 is mainly localized in the proximal tubules, urine
MCP-1 concentrations may mirror their function.
Table 2: Serum concentrations of examined parameters in CKD children and in the control group.
Parameters in serum
Median value (lower-upper quartile)
Control group (n = 23) CKD I (n = 20) CKD II (n = 41)
sMCP-1 (ng/ml) 348.3 (328.9–432.2) 1157.6a (1143.2–1183.7) 994.3b (977.2–1013.0)
sMCSF (pg/ml) 258.2 (253.7–265.0) 874.2a (864.9–895.4) 989.2b (965.4–1031.3)
s neopterin (ng/ml) 23.3 (22.8–23.5) 92.9a (91.9–95.5) 84.5b (82.4–88.0)
Mann–Whitney U test: ap < 0 0001, CKD I versus the control group. bp < 0 001, CKD II versus CKD I.
Table 3: Urine concentrations of examined parameters in CKD children and in the control group.
Parameters in urine
Median value (lower-upper quartile)
Control group (n = 23) CKD I (n = 20) CKD II (n = 41)
uMCP-1 (ng/mg creatinine) 88.4 (78.5–101.2) 872.5a (798.4–940.2) 804.4 (658.4–924.8)
uMCSF (pg/mg creatinine) 1004.4 (963.7–1125.2) 6948.4a (6296.9–7566.2) 5940.8b (5441.8–7464.7)
u neopterin (ng/mg creatinine) 112.31 (101.1–131.6) 300.1a (282.1–324.3) 501.76b (446.2–667.0)
Mann–Whitney U test: ap < 0 0001, CKD I versus the control group. bp < 0 01, CKD II versus CKD I.
Table 4: Fractional excretion of examined parameters in CKD children and in the control group.
Fractional excretion (FE) of parameters
Median value (lower-upper quartile)
Control group (n = 23) CKD I (n = 20) CKD II (n = 41)
FE MCP-1 (%) 0.18 (0.14–0.19) 0.42a (0.36–0.47) 1.58b (0.89–3.02)
FE MCSF (%) 2.79 (2.63–3.06) 4.40a (3.93–4.93) 11.67b (6.72–21.18)
FE neopterin (%) 4.53 (3.64–5.32) 5.96 (5.36–6.63) 6.49b (4.21–11.80)
Mann–Whitney U test: ap < 0 0001, CKD I versus control group. bp < 0 00001, CKD II versus CKD I.
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Of note, the fractional excretion, never tested in the case
of MCP-1, might be of an added value in the assessment of
tubular status quo. Indeed, the values of FE MCP-1 in CKD
stages 1-2, significantly higher than in controls, but not
exceeding 1%, seemed to confirm the early inflammatory
process in the tubules, preceding their damage. The latter
has become evident in CKD stages 3–5, when FE values kept
rising and exceeded 1%. Thus, fractional excretion could be a
useful tool in distinguishing between the inflammatory over-
activity and irreversible tubule damage, resulting in excessive
excretion of MCP-1 with urine.
The role of FE MCP-1 in the assessment of tubular
damage might be strengthened by the fact that, in children
with CKD stages 3–5, the MCP-1 serum concentration
declined, whereas the urinary one remained stable, in com-
parison to patients with CKD stages 1-2. Therefore, mono-
cyte activity seemed either to diminish (as in serum) or to
become stable (as in urine) in the course of advanced CKD.
Hence, FE MCP-1 rising values have shown the switch
from the inflammatory profile in early CKD to the tubular
dysfunction in late stages of the disease.
MCSF is another inflammation marker connected with
macrophage activity and migration. Similar to MCP-1, both
serum and urine concentrations rose in the early stages of
CKD, independent of eGFR values, and serum concentra-
tions did not correlate with the urinary ones. Like in the case
of MCP-1, no comparative data from other studies exist.
However, such increment in serum could be interpreted as
a result of macrophage activation and inflammation rather
than accumulation of the molecule, whereas the rise in
urine might be the result of MCSF generation by renal
parenchyma. Contrary to MCP-1, the serum MCSF values
continued to rise with CKD progression, whereas the urine
concentrations declined. Yet, the values of MCSF in urine
outreached those in serum, in controls as well as in
patients, irrespective of the CKD stage. Thus, probably
MCSF has shown more propensity towards the activity
of macrophages in serum than of those in renal interstitium.
The decline of MCSF urine concentrations could also mirror
the progression of renal fibrosis, which is macrophage-
mediated in its early stages, but then becomes independent
of cellular activity and irreversible.
Some of those uncertainties have clarified when the data
on fractional excretion were taken into account. The FE
MCSF values exceeded 1% already in controls and kept
rising with the progression of CKD. Therefore, MSCF pres-
ence in urine most probably resulted from its renal produc-
tion, which seems a constant feature, independent of renal
function. Consequently, the FE MCSF values, aggravating
with renal failure progression, could signify early inflam-
matory overactivity in renal parenchyma of CKD stages
1-2 and then renal fibrosis and tubular damage in CKD
stages 3–5.
Neopterin was the last analyzed parameter connected
with monocyte-macrophage activity and inflammation.
The increased molecule concentrations in serum and urine,
seen in all CKD children, were concordant with previous
observations concerning adults with advanced CKD [9].
Yadav et al. [10] have noticed the serum concentrations
of neopterin, increasing with declining eGFR in adults with
CKD stages 3–5, and on hemodialysis. However, the com-
parison of those results with ours seems difficult, since the
adult population, with diabetic and hypertensive nephropa-
thy responsible for additional inflammatory triggers, differs
from children with congenital anomalies in the urinary
tract as a main cause of CKD. Meanwhile, our observation
was the first one in the pediatric population and in the
early stages of CKD.
Like in the case of MCSF, the neopterin values in urine
were higher than the ones in serum, even in the control
group, and did not correlate with each other. The serum
neopterin concentrations in CKD stages 3–5 diminished
versus those in CKD stages 1-2, mimicking the activity of
MCP-1. Thus, neopterin in serum seemed dedicated to
monocyte rather than macrophage activity. In the meantime,
neopterin has shown the unique systematic increment of the
urine values, with significant differences between early and
late stages of CKD. This would make urinary neopterin a
good candidate marker of late changes in renal parenchyma,
like persistent inflammation facilitating progression of renal
failure [1].
The FE values of neopterin seemed to confirm this
hypothesis, since they remained unchanged in CKD stages
1-2 versus controls and then rose significantly in CKD stages
3–5. Moreover, they were above 1%, both in controls and in
CKD children, suggesting neopterin is produced by the
healthy renal parenchyma and, to a greater extent, by the
damaged tissue. Thus, FE neopterin values in advanced
CKD could mirror the extent of tubular damage due to
persistent inflammation.
Taken together, the complex analysis of serum, urine, and
fractional excretion values of examined parameters enabled
differentiation between early and persistent inflammation,
as well as analysis of the progression of tubular damage.
5. Conclusions
Fractional excretion of the examined markers may become a
useful tool in the assessment of inflammation and tubular
damage in the course of chronic kidney disease. The FE
MCP-1 values show that the inflammatory process precedes
the tubular dysfunction. FE MCSF and FE neopterin may
be considered new markers of renal parenchyma progressive
damage in children with CKD.
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